LA
VRTX icon

Latitude Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Latitude Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-855
Closed -$223K – 319
2022
Q1 		$223K Buy
+855
New +$203K 0.05% 301

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Latitude Advisors's VRTX Position: Q2 2022 in Review

Latitude Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 855 shares — an estimated $223K sold.

Latitude Advisors first reported a position in VRTX in Q1 2022 and held it in 1 quarter. The position peaked at $223K in Q1 2022. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • Latitude Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Latitude Advisors sold 855 Vertex Pharmaceuticals shares in Q2 2022, an estimated $223K.
  • Latitude Advisors first reported a position in Vertex Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Latitude Advisors's Vertex Pharmaceuticals position peaked at $223K in Q1 2022.
  • 1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Latitude Advisors's 13F filing for Q2 2022, filed 28 Jul 2022.